Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02750085
Other study ID # myPKFiT™ Study
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 2016
Est. completion date December 2020

Study information

Verified date May 2020
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an investigator-initiated, industry-funded, multi-centre, international study that will be carried out prospectively at hemophilia treatment centres across Canada, the Czech Republic and Australia with SickKids as the coordinating site. The study will use a central laboratory not directly affiliated with any of the participating sites. Enrollment target is 50 participants, both adult and pediatric with severe hemophilia A receiving Advate, who will each complete a 2-point and 6-point pharmacokinetic (PK) sampling. The main aim is to compare the results of a 2 sample PK using clinically practical time points and myPKFiT™ (a web-based, population PK Bayesian tool) to a 6 sample population PK to determine whether the results obtained are in good agreement.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 39
Est. completion date December 2020
Est. primary completion date January 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Confirmed diagnosis of Hemophilia A;

- Severe disease (FVIII <2%);

- Receiving ADVATE for prevention of bleeding (prophylaxis) or receiving ADVATE on demand and a candidate for prophylaxis;

- Body weight =120 kg; and =12kg;

Exclusion Criteria:

- FVIII inhibitor positive (level of =0.6 Bethesda Units [BU] per mL using the Nijmegen modification of the Bethesda assay). Inhibitor status to be documented as negative prior to study enrollment according to the two most recent, consecutive inhibitor assays on record. If patients have < 50 exposure days, an assay will be completed centrally within a reasonable timeframe (approximately 8 weeks suggested) to make sure that they are negative.

- Body weight >120 kg or <12kg;

- Human immunodeficiency virus (HIV) positivity with cluster of differentiation 4 (CD4) count < 200 / microliter;

- Significant hepatic dysfunction, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5 times upper limit of normal

- History of recent events that might affect FVIII half-life (e.g., infection, surgery or an invasive procedure) within 2 weeks of blood sampling.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (9)

Lead Sponsor Collaborator
Victor Blanchette Montreal Children's Hospital of the MUHC, Queen's University, Royal Children's Hospital, Royal Prince Alfred Hospital, Sydney, Australia, St. Paul's Hospital, Sydney Children's Hospitals Network, The University Hospital Brno, University Hospital, Motol

Outcome

Type Measure Description Time frame Safety issue
Primary Terminal half-life (t1/2) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary area under the plasma concentration versus time curve (AUC) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Area under the moment curve (AUMC) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary In vivo recovery (IVR) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Maximum concentration (Cmax) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Clearance (Cl) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Volume of distribution at steady state (Vss) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Mean residence time (MRT) 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
Primary Time to factor VIII concentration of 1% over baseline 2-point PK sampling protocol against 6-point PK sampling protocol 2 years
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1